Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 12.5% – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares rose 12.5% on Thursday . The stock traded as high as $3.76 and last traded at $3.9050. Approximately 6,754,697 shares were traded during trading, a decline of 60% from the average daily volume of 16,972,451 shares. The stock had previously closed at $3.47.

Trending Headlines about Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Analyst Ratings Changes

Several research firms have recently commented on RXRX. JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Bank of America dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Morgan Stanley raised their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.10.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $3.30 and its 200-day moving average is $3.82. The company has a market capitalization of $1.76 billion, a P/E ratio of -2.77 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% compared to the same quarter last year. During the same period last year, the business earned ($0.50) EPS. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Najat Khan sold 28,298 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the completion of the transaction, the chief executive officer directly owned 2,262,085 shares in the company, valued at $7,577,984.75. This trade represents a 1.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the transaction, the chief financial officer owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. The trade was a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 154,228 shares of company stock worth $530,741 in the last three months. 8.43% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE increased its stake in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after acquiring an additional 384,486 shares in the last quarter. Janus Henderson Group PLC increased its stake in Recursion Pharmaceuticals by 59.4% during the 1st quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock valued at $675,000 after purchasing an additional 82,100 shares in the last quarter. California State Teachers Retirement System increased its stake in Recursion Pharmaceuticals by 64.0% during the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after purchasing an additional 224,332 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Recursion Pharmaceuticals by 7.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock valued at $675,000 after purchasing an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at about $236,000. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.